Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1

• Download

Published in: Frontiers

Authors:

• Zachary D. Wallen
• Mary K. Nesline
• Alison Roos
• Erica Schnettler
• Hatim Husain
• Marni Tierno
• Pratheesh Sathyan
• Brian Caveney
• Marcia Eisenberg
• Eric A. Severson
• Shakti Ramkissoon